Phoenix, Arizona
CNS clinical trials in Phoenix, AZ
46 CNS studies are recruiting participants at sites in Phoenix as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Phoenix at a glance
- 46 studies are recruiting at a site in Phoenix.
- By phase: Phase 1/2 (1), Phase 2 (12), Phase 3 (17), Phase 4 (2), No phase (4), Observational (10). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (35), university, hospital or other (10), government (1).
- By research area: Depression (12), Epilepsy (10), Migraine (8), Parkinson's Disease (7), Multiple Sclerosis (5), Schizophrenia (4).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Phoenix
Basic details from each study's public record (the 30 most recently updated of 46). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- IMA Clinical Research Phoenix
- Registry record
- NCT07226661 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Mayo Clinic Hospital in Arizona
- Registry record
- NCT06748222 · updated
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- NoesisPharma, LLC
- Registry record
- NCT07775300 · updated
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Registry record
- NCT07621237 · updated
Study of ALTO-300 in MDD
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT05922878 · updated
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT07553637 · updated
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Draig Therapeutics Ltd
- Study site
- Draig Clinical Site
- Registry record
- NCT07610473 · updated
ALTO-100 in Bipolar Disorder With Depression (BD-D)
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT06656416 · updated
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Vanda Pharmaceuticals
- Study site
- Vanda Investigational Site
- Registry record
- NCT06830044 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Schizophrenia studies recruiting in Phoenix
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Phase 2
- Ages 55 to 90
- All sexes
- Sponsor
- MapLight Therapeutics
- Registry record
- NCT06887192 · updated
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- Southwest Autism Research and Resource Center
- Registry record
- NCT06229210 · updated
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- Banner Alzheimer's Institute
- Registry record
- NCT06585787 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Phoenix
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
- Observational
- All ages
- All sexes
- Sponsor
- Boston Scientific Corporation
- Study site
- St. Joseph's Hospital & Medical Center
- Registry record
- NCT03664609 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic Cancer Center ( Site 0034)
- Registry record
- NCT06966700 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Barrow Neurological Institute
- Registry record
- NCT07174310 · updated
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic in Arizona - Phoenix ( Site 0147)
- Registry record
- NCT06170788 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Phoenix
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 60
- All sexes
- Sponsor
- Zenas BioPharma (USA), LLC
- Study site
- Arizona Neuroscience Research, LLC
- Registry record
- NCT07299019 · updated
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT06433752 · updated
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study sites
- AZ Integrated Neuro and Spine · Ctr for Neurology and Spine · Xenoscience Inc
- Registry record
- NCT07225504 · updated
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Phase 3
- Ages 18 to 60
- All sexes
- Sponsor
- Sanofi
- Study site
- Center for Neurology and Spine - Phoenix - East Bell Road- Site Number : 8400195
- Registry record
- NCT07325292 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Epilepsy studies recruiting in Phoenix
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- Xenoscience
- Registry record
- NCT05667142 · updated
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Neurona Therapeutics
- Study site
- Mayo Clinic Arizona Epilepsy Center
- Registry record
- NCT05135091 · updated
Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)
- Observational
- Ages 6 and older
- All sexes
- Sponsor
- CREmedical
- Study site
- Barrow Neurological Institute Dignity Health dba St. Joseph's Hospital and Medical Center
- Registry record
- NCT05944692 · updated
Diagnosing Epilepsy To EffeCT Change
- No phase
- Ages 18 to 75
- All sexes
- Sponsor
- Epiminder America, Inc.
- Study site
- Mayo Clinic - Arizona
- Registry record
- NCT07110337 · updated
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
- Observational
- Ages 18 to 75
- All sexes
- Sponsor
- Epiminder America, Inc.
- Study site
- Mayo Clinic - Arizona
- Registry record
- NCT07110454 · updated
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study sites
- Banner University Medical Center-Phoenix · Xenoscience
- Registry record
- NCT06798896 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Migraine studies recruiting in Phoenix
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic Arizona
- Registry record
- NCT06972056 · updated
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- IMA Clinical Research - Phoenix · Velocity Clinical Research, Phoenix
- Registry record
- NCT07816367 · updated
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Aspeya, Inc.
- Study site
- Arizona Research Center
- Registry record
- NCT07646613 · updated
Responding With Evidence and Access for Childhood Headaches
- No phase
- Ages 10 to 17
- All sexes
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Study site
- Phoenix Children's Hospital - Barrow Neurological Institute
- Registry record
- NCT05889624 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Phoenix, AZ on ClinicalTrials.gov.
Ask about studies near Phoenix
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections